KAZIA THERAPEUTICS LTD (KZIA) research

KAZIA THERAPEUTICS LTD

Sector: Healthcare
Industry: Biotechnology
Last price: $9.27
As of: 2026-10-02

KAZIA THERAPEUTICS LTD (KZIA): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-22.

As of 2026-09-22, the latest of: this ticker's 13F holdings load, its latest SEC filing date, and its latest signal other than 13F-derived signals. Source: SEC EDGAR filings for KZIA. Method and limitations.

COMPANY DOSSIER

See the full KZIA dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for KZIA on one page. Preview it with sample data, then open it live with a free account.

Preview the KZIA dossier

Active signals for KZIA

highCONSENSUS_BUY2026-09-16
3 tracked funds increased KZIA this 2026Q2, institutional consensus
All 2026-09-16 signals →
mediumNEW_POSITION2026-08-16
MILLENNIUM MANAGEMENT LLC new position in KZIA
All 2026-08-16 signals →
mediumNEW_POSITION2026-08-16
CITADEL ADVISORS LLC new position in KZIA
All 2026-08-16 signals →
mediumEARNINGS_MISS2026-06-23
Q4-2023: Missed consensus by 272.5% - EPS $-9.5 vs $-2.55 estimate
All 2026-06-23 signals →
mediumEARNINGS_BEAT2026-06-23
Q2-2025: Beat consensus by 29.5% - EPS $-12.3 vs $-17.442 estimate
All 2026-06-23 signals →

FREE, NO ACCOUNT

Every signal on KZIA, as it fires

You are seeing 5 of 10 signals recorded on KZIA since 2026-05-30.

The five above landed across 3 days. The other 5 were recorded on 1 other days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in KZIA (2026Q2)

Manager / security	Market value	% portfolio	QoQ
Point72 Asset Management, L.P.CUSIP 48669G303 · 2026Q2	$2.3M	0.00%	,
MILLENNIUM MANAGEMENT LLCCUSIP 48669G303 · 2026Q2	$1.4M	0.00%	,
CITADEL ADVISORS LLCCUSIP 48669G303 · 2026Q2	$401K	0.00%	,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, KZIA

6-K2026-09-22
SEC EDGAR ↗
6-K2026-09-18
SEC EDGAR ↗
6-K2026-09-01
SEC EDGAR ↗
6-K2026-08-31
SEC EDGAR ↗
6-K2026-08-31
SEC EDGAR ↗
6-K2026-08-28
SEC EDGAR ↗
6-K2026-08-27
SEC EDGAR ↗
6-K2026-07-28
SEC EDGAR ↗
6-K2026-06-02
SEC EDGAR ↗
6-K2026-05-26
SEC EDGAR ↗

KZIA against its peers

KZIA's net margin of -49290.5% ranks in the 14th percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2024-12-31 and 2025-12-31.

Metric	KZIA	Peer median	Percentile	n
Revenue FY	42000 AUD	n/a	n/a	0
Revenue YoY	-98.2%	n/a	n/a	1
Operating margin	n/a	-518.8%	n/a	10
Net margin	-49290.5%	-501.2%	14	10
Return on equity	n/a	-87.9%	n/a	19

Peers (22): VXRT, PYPD, OKUR, MNOV, BDTX, IMUX, AARD, MIST, CBUS, LENZ, VANI, SPRC, PLYX, ANIX, GNLX, COYA, PMN, UNCY, NMRA, CRBP, FHTX, CRDF. Left out: CNXU (no annual filing), NTRB (period gap), HSTC (period gap). Fiscal periods ending between 2024-12-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (KZIA: 20-F), reported in AUD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more KZIA signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to KZIAand get the insider, 13F, options, and confluence read in one view.